Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

DSIP

Delta Sleep-Inducing Peptide · WAGGDASGE

Animal replicated

Research chemicalSleep Peptide Nonapeptide Neuropeptide

RouteInjectableGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: Delta Sleep-Inducing Peptide / Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu / WAGGDASGE — Sleep Peptide, Nonapeptide, Neuropeptide.
Why people use it: Used primarily for cognitive support and sleep and recovery.

If you only read one thing

Isolated 1977. Named for Sleep. 40+ Years of Research. No Gene Found. No Specific Receptor Identified. Half-Life 15 Minutes In Vitro — Yet Produces Multi-Night Effects. Studied for Sleep, Stress, Alcohol Withdrawal, Opiate Withdrawal, Neuroprotection, and Longevity. The Most Mechanistically Mysterious Compound in this reference.

Check interactions →

Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit

Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat

Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor

Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot

See route notes

Evidence varies by use case

Published literature

1human RCT4human studies6animal1in vitro

Evidence reality check

Human evidence

5 human studies

1 randomized; 4 observational.

Preclinical base

7 lab signals

6 animal; 1 in-vitro/mechanistic.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Cognition & Mood Sleep & Recovery

Properties

✓ Human RCTNot injectable

Half-life

In animal studies: the half-life appears even shorter — approximately 4-5 minutes in vivo

Evidence

CAnimal replicated

The Scientific Mystery

DSIP holds a unique distinction in neuropeptide science: it is the only well-characterized neuropeptide for which no encoding gene and no specific receptor have been found after more than four decades of investigation. This creates fundamental questions about its true nature: Is it cleaved from a larger precursor protein that has not yet been identified? Does it act through multiple receptor systems non-specifically (GABA-A, NMDA, opioid)? Is the DSIP-like material detected in human blood truly the same molecule as rabbit-isolated DSIP? No definitive answers exist. Mechanistic claims in DSIP research should be understood against this background of fundamental scientific uncertainty.

The Half-Life Paradox

In vitro, DSIP has a half-life of approximately 15 minutes due to a specific aminopeptidase that cleaves the Trp residue at position 1, followed by further degradation. In animal studies, the half-life appears even shorter (4-5 minutes). This should make DSIP essentially pharmacologically useless at peripheral doses — it would be degraded before reaching the CNS. Yet clinical studies show multi-night lasting sleep effects from a single IV dose. The proposed explanation: DSIP may bind to carrier proteins in vivo that protect it from degradation; or its degradation fragments may themselves be biologically active; or the very short in vivo half-life is compensated by high potency at very low concentrations. None of these explanations have been conclusively demonstrated.

Sleep Evidence — Small But Interesting

The most directly relevant human evidence: Schneider-Helmert and Schoenenberger (1981): IV DSIP (25 nmol/kg) in 6 chronic insomniacs — longer sleep duration, higher quality, fewer interruptions, no daytime sedation; effects persisted for multiple subsequent nights. Bes et al. (1992): double-blind, placebo-controlled trial in 14 chronic insomniacs — substantially improved sleep quality. Schneider-Helmert (1981 pilot): 7 severe insomniacs, 10 IV injections — sleep normalized in 6 of 7, maintained for 3-7 months. Grade C overall — real effects in small studies; no modern large RCT. The multi-night persistence and absence of sedation distinguish DSIP from conventional sleep medications.

Community Uses Beyond Sleep

Community use of DSIP has expanded well beyond sleep optimization. Current community applications: sleep quality and SWS enhancement; stress resilience and HPA axis normalization; anxiety reduction (adaptogenic framing); neuroprotection in aging/longevity stacks; antioxidant support; alcohol withdrawal management; opiate withdrawal support. The evidence base varies dramatically by application — from small but interesting trials (sleep, withdrawal) to animal-only data (antioxidant, neuroprotection) to purely mechanistic extrapolation (longevity). All community applications beyond sleep are Grade C-E.

Administration

Injectable (SubQ): most reliable delivery; typical community doses 100-300 mcg SubQ 30-60 minutes before sleep; 2-3x per week rather than daily. Nasal spray: variable bioavailability (2-18% depending on formulation and mucosal condition); less invasive; widely available commercially. Oral: disputed — one Caco-2 cell model study suggested DSIP cannot cross the GI epithelium; oral bioavailability likely minimal. No FDA-approved pharmaceutical form. No pharmaceutical standard; quality entirely dependent on vendor. Not WADA-prohibited.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

Oxytocin

Same class · Nonapeptide

The First Peptide Ever Synthesized (Nobel Prize 1955). FDA-Approved for Obstetric Use Since the 1950s. The 'Love Hormone' That Science Has Substantially Complicated. Intranasal Bioavailability ~2%. Trust Enhancement Replication Failures. Autism Trials: Mixed to Null. Context-Dependent Effects That Can Go Either Direction. And an OTC Nasal Spray Industry Built on Evidence That Doesn't Support What It Claims.

VIP

Same class · Neuropeptide

The Most Physiologically Broad Compound in this reference. 28 Amino Acids. Every System in the Body. VPAC1 and VPAC2. The 90-Second Half-Life Problem That Blocked IV Use. How Intranasal Administration Changed Everything. Dr. Shoemaker's CIRS Protocol: 300+ Physicians, 90%+ Symptom Reduction. The Long-COVID Connection. Aviptadil COVID ARDS Trials. The Mast Cell / MCAS Intersection. Why the Community Uses It and What the Evidence Actually Shows.

Epitalon

Shared goal · cognition

40 Years of Research From One Lab. The Most Cited Telomere Peptide in the Longevity Space. The First Independent Replication Was Published in 2025.